Thyme Care was featured in Endpoints News for raising $97 million in its Series D round, which pushes its valuation above $1 billion. The article frames this milestone as a key moment in health tech, emphasizing that the new funding further validates the company’s value-based approach to cancer care navigation. Focused on scaling operations and deepening clinical integration, the round is positioned as a catalyst for expansion and continued innovation in oncology care.